摘要
目的观察研究依达拉奉联合氯吡格雷治疗急性脑梗死的临床效果及安全性。方法选取2014年2月~2015年2月长兴县人民医院神经内科收治疗的诊断为急性脑梗死的患者80例,按随机数字表法分为观察组和对照组各40例。对照组给予氯吡格雷基础治疗,观察组在对照组的基础上给予依达拉奉治疗,分析治疗结束后2组患者血清超氧化物歧化酶（superoxide dismutase,SOD）、丙二醛（malondialdehyde,MDA）水平。结果治疗7、14 d后观察组血清SOD水平分别为（89.37±6.07、99.14±11.24）U/m L均高于对照组的（71.26±7.43、80.01±12.02）U/m L（P〈0.05）。治疗7 d、14 d后观察组血清MDA水平分别为（5.23±0.81、3.42±0.48）nmol/m L,均低于对照组的（7.16±1.01、5.24±0.71）nmol/m L（P〈0.05）。结论依达拉奉联合氯吡格雷治疗急性脑梗死的临床效果确切,且患者耐受性好。
Objective To observe the clinical effect of edaravone combine with clopidogrel on patients with acute cerebral infarction.Methods Eighty cases diagnosed with acute cerebral infarction from February 2014 to February 2015 were randomly divided into observation group and control group with 40 cases in each group. Control group received basic treatment of clopidogrel,observation group received edaravone on the basis of control group. The serum levels of superoxide dismutase（ SOD） and malondialdehyde（ MDA） between two groups were compared post-treatment.Results The serum SOD levels in observation group on 7thand 14 thday post-treatment [（ 89. 37 ± 6. 07,99. 14 ± 11. 24） U / m L]were significantly higher than those in control group [（ 71. 26 ± 7. 43,80. 01 ± 12. 02） U / m L]（ P〈0. 05）. The serum MDA levels in observation group on 7thand 14 thday posttreatment [（ 5. 23 ± 0. 81,3. 42 ± 0. 48） nmol / m L]were significantly higher than those in control group[（ 7. 16 ± 1. 01,5. 24 ± 0. 71） nmol / m L]（ P〈0. 05）. Conclusion Edaravone combined with clopidogrel has the exact effect in treatment of patients with acute cerebral infarction.
出处
《中国生化药物杂志》
CAS
2015年第12期158-159,共2页
Chinese Journal of Biochemical Pharmaceutics
基金
浙江省中医药科技计划项目(2009YB028)
关键词
依达拉奉
氯吡格雷
联合用药
急性脑梗死
edaravone
clopidogrel
combination therapy
acute cerebral infarction
